News Releases

Date Title and Summary
Toggle Summary electroCore to Announce Fourth Quarter and Year Ended December 31, 2021 Financial Results on Thursday, March 10
Conference Call to be Held at 4:30 PM Eastern Standard Time ROCKAWAY, N.J. , March 03, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that it will report financial results for the fourth quarter and year ended December
Toggle Summary Data Presented at 2022 International Stroke Congress Suggests Role for Non-invasive Vagus Nerve Stimulation (nVNS) for Treatment of Acute Stroke
Clinical Trial (n=69) suggests safety and feasibility of nVNS for the acute treatment of stroke. Relative Ischemic Lesion Growth Decreased by 65.9% with nVNS vs. Sham Treatment. ROCKAWAY, N.J. , Feb. 09, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc.  (Nasdaq: ECOR), a commercial-stage bioelectronic
Toggle Summary electroCore, Inc. Announces Completion of Enrollment in the TRANSIT Study of non-Invasive Vagus Nerve Stimulation (nVNS) in Post-Operative Ileus
Data on 97-patient, randomized, sham-controlled study to be presented at medical congress later this year ROCKAWAY, N.J. , Feb. 01, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc.  (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced enrollment has been completed for the
Toggle Summary electroCore, Inc. Announces Three Abstracts to be Presented at International Stroke Conference 2022
Clinical Research Conducted on Non-invasive Vagus Nerve Stimulation (nVNS) for the Acute Treatment of Stroke ROCKAWAY, N.J. , Jan. 25, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc.  (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced three abstracts focusing on the
Toggle Summary electroCore Announces Shareholder Letter and Full-Year 2021 Business Update
Company anticipates full-year 2021 revenue of approximately $5.5 million, an approximately 55% increase over full-year 2020 ROCKAWAY, N.J. , Jan. 18, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) today published a letter from the company’s Board of Directors to shareholders.
Toggle Summary gammaCore™ Non-Invasive Vagus Nerve Stimulation(nVNS) Receives Breakthrough Device Designation for Treatment of Posttraumatic Stress Disorder (PTSD)
nVNS reduces symptoms of PTSD by 31% in sham-controlled study ROCKAWAY, N.J. , Jan. 12, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc.  (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that its gammaCore™ nVNS device has received Breakthrough Designation from the
Toggle Summary electroCore, Inc. Broadens Patient Access to gammaCore with Launch of U.S. Telehealth Portal and Online Store
ROCKAWAY, N.J. , Jan. 11, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the launch of an e-commerce shop for patients residing in the United States . The site, which can be accessed through www.gammacore.com , allows
Toggle Summary electroCore Announces Publication of PREMIUM II Trial of gammaCore (Non-Invasive Vagus Nerve Stimulation; nVNS) for the Prevention of Migraine
ROCKAWAY, N.J. , Jan. 10, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc.  (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a peer-reviewed paper, entitled “Non-invasive vagus nerve stimulation for prevention of migraine: The multicenter, randomized,
Toggle Summary electroCore to Present at H.C. Wainwright BIOCONNECT Virtual Conference
ROCKAWAY, NJ , Jan. 04, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that its management team will give a presentation at the H.C. Wainwright BIOCONNECT Virtual Conference .
Toggle Summary electroCore, Inc. Provides Update on Global Distribution Partners
ROCKAWAY, NJ , Dec. 16, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced it has entered into agreements with Melidonia Health Services (Melidonia), Cyrus Medical Technologies (Cyrus), and Express Medical